QR 334

Drug Profile

QR 334

Latest Information Update: 16 Nov 2005

Price : $50

At a glance

  • Originator Quigley Pharma
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Sialorrhoea

Most Recent Events

  • 09 Nov 2005 Discontinued - Phase-II for Sialorrhoea in USA (unspecified route)
  • 22 Jul 2002 Phase-II clinical trials in Sialorrhoea in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top